Press release from Companies
Published: 2024-12-12 16:25:42
The subscription period in Phase Holographic Imaging PHI AB’s ("PHI" or the "Company") fully secured rights issue, totalling SEK 64.3 million, is ongoing until 20 December 2024. The Company’s CEO, Anders Månsson, has during the last couple of weeks presented the Company and its future plans at BioStock, Aktieportföljen Live and Financial Stockholm. Månsson has also been interviewed by the podcast Fill or Kill, to give more insight to the Company and its market potential. For links to the presentations and the podcast, see below.
Investor presentations and podcast
BioStock 3 December 2024
Link: BioStock
Aktieportföljen Live 10 December 2024
Link: Aktieportföljen Live
Fill or Kill 10 December 2024
Link: Fill or Kill
Financial Stockholm 11 December 2024
Link: Financial Stockholm
Prospectus and how to subscribe
The subscription period runs until 20 December 2024. A prospectus containing more information about PHI and the rights issue is available on the Company’s website, www.phiab.com, on Spotlight Stock Market’s website, www.spotlightstockmarket.com as well as on Nordic Issuing AB’s website, www.nordic-issuing.se. Those interested in subscribing for shares in the rights issue should contact their banks for details on deadlines (since these may vary between banks) and instructions or visit www.nordic-issuing.se.
Advisors
Navia Corporate Finance AB is the financial advisor and Sole Bookrunner in connection with the rights issue. HWF Advokater AB is the legal advisor. Nordic Issuing AB is the issuing agent.
For more information about the rights issue, please contact:
Navia Corporate Finance AB
E-mail: info@naviacf.se
Website: www.naviacorporatefinance.com
For additional information, please contact:
Anders Månsson
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.
